KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.

Trial Details

NCT ID
NCT05483491
Phase
PHASE1
Sponsor
Christian Hinrichs
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • KK-LC-1 TCR-T cells
  • Aldesleukin
Locations (sample)
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

  • Signed, written informed consent obtained prior to any study procedures.
  • Age ≥ 18 years at the time of informed consent.
  • Metastatic solid tumor with ≥ 10% of tumor cells positive for KK-LC-1 by IHC assay. Due to the low frequency of KK-LC-1 expression in most cancers,…
  • HLA-A\*01:01 allele by HLA haplotype test.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →